Reportlinker Adds Global Rheumatoid Arthritis Therapeutics Industry

NEW YORK,  March 9 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Global Rheumatoid Arthritis Therapeutics Industry

http://www.reportlinker.com/p0181060/Global-Rheumatoid-Arthritis-Therapeutics-Industry.html

This report analyzes the worldwide markets for Rheumatoid Arthritis Therapeutics in US$ Million. The report provides separate comprehensive analytics for US, Japan, Europe, Latin America and Rest of World. Annual forecasts are provided for each region for the period 2006 through 2015. The report profiles 103 companies including many key and niche players worldwide such as Abbott Laboratories, Inc., Amgen, Inc., Biogen Idec, Inc., Bristol-Myers Squibb Company, F. Hoffmann-La Roche AG, Chugai Pharmaceutical Co., Ltd., Genentech Inc., Genmab AS, GlaxoSmithKline PLC, Johnson & Johnson Services, Inc., Schering-Plough Corp., UCB S.A., and Wyeth. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.

RHEUMATOID ARTHRITIS THERAPEUTICS MCP-1498

A GLOBAL STRATEGIC BUSINESS REPORT

CONTENTS

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

Study Reliability and Reporting Limitations I-1

Disclaimers I-2

Data Interpretation & Reporting Level I-3

Quantitative Techniques & Analytics I-3

Product Definitions and Scope of Study I-3

II. EXECUTIVE SUMMARY

1. INDUSTRY OVERVIEW & OUTLOOK II-1

Global Pharmaceutical Industry Hit by Economic Downturn II-1

Credit Crunch to Affect Biological Drug Pipeline II-1

Biotech Bankruptcies Rife in the Current Economic Downturn II-1

Economic Downturn Takes Toll on R&D II-2

Autoimmune Disease Therapeutics - An Ever Flourishing Market II-2

Rheumatoid Arthritis - A Chronic, Debilitating Disease II-2

Incidence and Prevalence Higher in Urban and Developed Regions II-3

Rheumatoid Arthritis - Market Overview II-3

A Look At Arthritis Market Sales Data II-4

Table 1: World Arthritis Market - Value Sales of Drug

Classes for 2006 and 2007 (USD billion) (includes

corresponding Graph/Chart) II-4

Table 2: World Arthritis Market - Value Sales of Anti- TNF

Biologics for 2007 (USD billion) (includes corresponding

Graph/Chart) II-4

Table 3: World Arthritis Market -Value Sales of Select

NSAIDs for 2007 (USD billion) (includes corresponding

Graph/Chart) II-5

Table 4: World Arthritis Market - Value Sales of COX-2

Inhibitors for 2007 (USD billion) II-5

Market Outlook II-5

Global Market Estimates and Forecasts II-6

2. MARKET DYNAMICS AND TRENDS II-7

Anti-TNF Biologic Therapies - The Market Leading RA Drugs II-7

Table 5: World Rheumatoid Arthritis Market - Value Sales* of

Biologic Response Modifiers: 2007 and 2008 (in US$ Billion)

(includes corresponding Graph/Chart) II-7

Biologics Continue to Gain Market Share II-8

Expensive Biologics to Drive Value Growth II-8

Year of Approval of Leading Biologics in Rheumatoid

Arthritis Therapy II-8

New Products to Drive Market Growth II-9

Superior Outcomes to Enhance Adoption of Biologics II-9

Efficacy and Convenience - Key Factors Driving Physician's

Decision II-9

Non-Anti-TNFs, Orencia to Gain Strength II-9

Patent Expiry - A Mid- to Long-term Threat II-10

Year of Expected Generic Market Entry of Leading Biologics

in Rheumatoid Arthritis Therapy II-10

Competitive Landscape II-10

Table 6: Comparative Analysis of Leading Biologic Rheumatoid

Arthritis Drugs based on ACR Scores by End Point (includes

corresponding Graph/Chart) II-12

High Prices and Safety Concerns II-12

3. RHEUMATOID ARTHRITIS: THE DISEASE AND TREATMENT II-14

Arthritis II-14

Rheumatoid Arthritis II-14

The Disease Progression II-14

The Age Factor II-14

Causes and Diagnosis II-15

Signs and Symptoms II-15

Treatment II-15

Non-steroidal Anti-inflammatory Drugs II-16

Side Effects Profile II-16

Cyclo-Oxygenase-2 Inhibitors II-16

Celecoxib II-17

Others II-17

Anti-rheumatic Steroids II-17

Side Effects Profile II-18

Corticosteroids II-18

Glucocorticoids II-18

Disease-modifying Anti-rheumatic Drugs (DMARDs) II-18

D-penicillamine II-19

Gold Salts II-19

Hydroxychloroquine II-19

Leflunomide II-19

Methotrexate II-20

Sulfasalazine II-20

Others II-20

Biological Response Modifiers II-20

Adalimumab (Humira) II-21

Etanercept II-22

Infliximab II-22

Anakinra II-23

Abatacept II-24

Rituximab II-25

Tocilizumab II-26

4. DRUG DEVELOPMENT FOCUS II-27

The Rheumatoid Arthritis Pipeline II-27

List of Select RA Drug Candidates in Various Clinical

Pipeline Phases: 2008-09 II-27

Opportunities Aplenty for New Oral Agents in RA Treatment II-28

5. RESEARCH & DEVELOPMENT II-30

Velcura to Commence Clinical Trials for Lead Rheumatoid

Arthritis Compound II-30

Biogen Announces Phase II Trial Results for Baminercept in

Rheumatoid Arthritis II-30

Genentech, Biogen Announce Encouraging Phase III Results of

Rituxan II-30

Chelsea Announces Encouraging Preclinical Results for RA Drug

Candidate II-31

Medarex Commences Phase II Trials for Rheumatoid Arthritis

Treatment Drug II-31

ChemoCentryx Launches Phase I Clinical Trial for CCR1 Inhibitor II-31

Chelsea Commences Phase II Trial for CH-1504 II-31

Arana Therapeutics Initiates Phase II Trial of ART621 in

Rheumatoid Arthritis II-31

VGX Pharma Initiates Follow-on Phase I Study for VGX-1027 II-32

Genmab to Commence Phase I/II Trial of Ofatumumab in RA Patients II-32

Can-Fite Announces Seikagaku's Proposed Phase I Trial for

CF101 in Japan II-32

Hollis-Eden Pharma Initiates Phase I/II Trial of Triolex in

RA Patients II-32

Trubion Pharma Announces Initiation of Phase 1 Trial of SBI-087 II-32

Micromet and Nycomed Initiate Formal Preclinical Safety Studies II-33

6. RECENT INDUSTRY ACTIVITY II-34

GlaxoSmithKline Forms Strategic Alliance with Archemix II-34

Cypress Bioscience Acquires Proprius Pharmaceuticals II-34

Biotie to Takeover German Company, elbion II-35

Roche to Acquire UK Company, Piramed II-35

Pipex Acquires Rheumatoid Arthritis Drug Candidate, dnaJP1 II-35

Latona Signs Two Agreements to Acquire Orphan Drug Status and

Patent Rights II-36

MorphoSys, Galapagos Sign Alliance to Co-Develop Antibody

Therapies II-36

Nycomed Inks Agreement with Immunomedics for Veltuzumab II-37

Affitech Signs Antibody Discovery and Development Deal with

Omeros II-38

Entelos Signs Research Agreement with UCB Pharma II-38

Novo Nordisk and VLST Form Partnership to Develop Therapeutic

Targets II-38

Maxygen Enters into Agreement with Astellas for MAXY-4 II-39

GlaxoSmithKline Forms Global Alliance with Regulus Therapeutics II-39

Can-Fite Signs License Agreement with Korean Company for RA Drug II-40

Amgen, Wyeth Announce U.S. Prescribing Information Update for

Enbrel II-40

Galapagos Secures Grant for Rheumatoid Arthritis Drug

Development II-40

MorphoSys and University of Melbourne to Receive U.S. Patent II-41

Merrimack Acquires Funds for Developing Biologics II-41

Galapagos Announces GT146 Milestone Achievement II-41

Amgen Acquires Avidia II-42

Iroko Acquires Two Pharmaceutical Products from Merck II-42

EvoGenix to Merge with Peptech II-42

Eli Lilly and MacroGenics Tie Up for Developing Teplizumab II-43

Pharmacopeia and Wyeth Sign R&D Agreement to Develop JAK3

Inhibitors II-43

Nuon Enters into Strategic Agreement with Kissei Pharmaceutical II-44

Roche and Toyama Enter into Licensing Agreement for T-5224 II-44

GSK and Genmab Sign Partnership Agreement for HuMaxCD20 II-45

7. PRODUCT APPROVALS / APPLICATIONS II-46

UCB Receives FDA Approval for Cimzia for Treating Rheumatoid

Arthritis II-46

Centocor Announces FDA Approval of Simponi™ for Rheumatoid

Arthritis II-46

Chugai Announces Japanese Approval of Actemra for RA Treatment II-46

Abbott Secures Japanese Approval for Humira for RA Treatment II-47

Chugai and Roche Secure Swiss Approval for RoACTEMRA II-47

Chugai and Roche Announce Further FDA Guidance on BLA for

Actemra II-47

Roche, Chugai Announce CHMP's Positive Recommendation for

RoActemra II-48

Roche's Actemra Recommended for Approval by FDA Advisory

Committee II-48

Centocor, Schering-Plough Submit MAA for Golimumab Approval II-48

UCB Submits MAA to the EMEA for Approval of Certolizumab Pegol II-48

Abbott Secures FDA Approval for Humira for Polyarticular JIA

Treatment II-49

Xian-Janssen Introduces Remicade, Branded infliximab in China II-49

Abbott Files for Humira Approval as JRA Treatment in the US

and Europe II-49

Roche Receives NICE Approval for MabThera as Severe RA Treatment II-49

8. FOCUS ON SELECT PLAYERS II-51

Abbott Laboratories, Inc. (USA) II-51

Amgen, Inc. (USA) II-51

Biogen Idec, Inc. (USA) II-52

Bristol-Myers Squibb Company (USA) II-53

F. Hoffmann-La Roche AG (Switzerland) II-54

Chugai Pharmaceutical Co., Ltd. (Japan) - A Member of Roche

Group II-55

Genentech Inc. (USA) II-55

Genmab AS (Denmark) II-56

GlaxoSmithKline PLC (UK) II-57

Johnson & Johnson Services, Inc. (USA) II-57

Schering-Plough Corp. (USA) II-58

UCB S.A. (Belgium) II-59

Wyeth (USA) II-59

9. GLOBAL MARKET PERSPECTIVE II-60

Table 7: World Recent Past, Current & Future Analysis for

Rheumatoid Arthritis Therapeutics (Biologics) by Geographic

Region - US, Japan, Europe, Latin America and Rest of World

Markets Independently Analyzed with Annual Revenue Figures in

US$ Million for Years 2006 through 2015 (includes

corresponding Graph/Chart) II-60

Table 8: World 10-Year Perspective for Rheumatoid Arthritis

Therapeutics (Biologics) by Geographic Region - Percentage

Breakdown of Dollar Revenues for the US, Japan, Europe, Latin

America and Rest of World Markets for 2006, 2009 & 2015

(includes corresponding Graph/Chart) II-61

III. MARKET

1. THE UNITED STATES III-1

A.Market Analysis III-1

Current & Future Analysis III-1

Rheumatoid Arthritis - Prevalence III-1

Table 9: US Rheumatoid Arthritis Patient Group Breakdown

for 2008 (includes corresponding Graph/Chart) III-1

Table 10: US Moderate to Severe Rheumatoid Arthritis

Patient Group Breakdown by Therapy for 2008 (includes

corresponding Graph/Chart) III-2

Market Overview III-2

Market Trends III-3

Biologic Drugs Lead the Fray III-3

Table 11: US Rheumatoid Arthritis Therapeutics Market -

Breakdown of Value Sales of Leading Biologic Therapies

for 2007 (includes corresponding Graph/Chart) III-3

Enbrel and Humira Continue to Gain Share in the Anti-TNF

Market III-3

Research and Development III-4

Strategic Corporate Developments III-6

Product Approvals III-10

Select Players III-12

B.Market Analytics III-18

Table 12: US Recent Past, Current & Future Analysis for

Rheumatoid Arthritis Therapeutics (Biologics) - Annual

RevenueFigures in US$ Million for Years 2006 through 2015

(includes corresponding Graph/Chart) III-18

2. JAPAN III-19

A.Market Analysis III-19

Current & Future Analysis III-19

Market Overview III-19

Table 13: Japanese Rheumatoid Arthritis Patient Group

Breakdown for 2008 (includes corresponding Graph/Chart) III-19

Research and Development III-20

Strategic Corporate Developments III-20

Product Approvals III-22

Select Player III-22

B.Market Analytics III-23

Table 14: Japanese Recent Past, Current & Future Analysis

for Rheumatoid Arthritis Therapeutics (Biologics) - Annual

Revenue Figures in US$ Million for Years 2006 through 2015

(includes corresponding Graph/Chart) III-23

3. EUROPE III-24

A.Market Analysis III-24

Current & Future Analysis III-24

Rheumatoid Arthritis - Prevalence III-24

Table 15: European Rheumatoid Arthritis Patient Group

Breakdown for 2008 (includes corresponding Graph/Chart) III-24

Market Overview III-25

Research and Development III-25

Strategic Corporate Developments III-25

Product Approvals III-30

Select Players III-32

B.Market Analytics III-35

Table 16: European Recent Past, Current & Future Analysis

for Rheumatoid Arthritis Therapeutics (Biologics) - Annual

Revenue Figures in US$ Million for Years 2006 through 2015

(includes corresponding Graph/Chart) III-35

4. LATIN AMERICA III-36

A.Market Analysis III-36

Current & Future Analysis III-36

B.Market Analytics III-36

Table 17: Latin American Recent Past, Current & Future

Analysis for Rheumatoid Arthritis Therapeutics (Biologics)

by Region - Brazil and Rest of Latin America Markets

Independently Analyzed with Annual Revenue Figures in US$

Million for Years 2006 through 2015 (includes corresponding

Graph/Chart) III-36

Table 18: Latin American 10-Year Perspective for Rheumatoid

Arthritis Therapeutics by Region - Percentage Breakdown of

Dollar Revenue for Brazil and Rest of Latin America Markets

for 2006, 2009 & 2015 III-37

5. REST OF WORLD III-38

A.Market Analysis III-38

Current & Future Analysis III-38

Canada III-38

Canadian Rheumatoid Arthritis Therapeutics Market III-38

Australia III-38

Overview of Rheumatoid Arthritis in Australia III-38

Table 19: Percentage Breakdown of Prevalence of Rheumatoid

Arthritis in Australia by Age Group (includes

corresponding Graph/Chart) III-39

Table 20: Percentage Breakdown of Prevalence of Rheumatoid

Arthritis in Australia by Gender (includes corresponding

Graph/Chart) III-39

Research and Development III-40

Strategic Corporate Developments III-40

Product Launch III-41

B.Market Analytics III-41

Table 21: Rest of World Recent Past, Current & Future

Analysis for Rheumatoid Arthritis Therapeutics (Biologics)-

Annual Revenue Figures in US$ Million for Years 2006 through

2015 (includes corresponding Graph/Chart) III-41

IV. COMPETITIVE LANDSCAPE

Total Companies Profiled: 103 (including Divisions/Subsidiaries - 110)

------------------------------------------

Region/Country Players

------------------------------------------

The United States 60

Canada 3

Japan 14

Europe 26

France 1

Germany 6

The United Kingdom 3

Rest of Europe 16

Asia-Pacific (Excluding Japan) 7

------------------------------------------

To order this report:

Therapy Industry: Global Rheumatoid Arthritis Therapeutics Industry

More  Market Research Report

Check our  Company Profile, SWOT and Revenue Analysis!

SOURCE Reportlinker

21%

more press release views with 

Request a Demo